论文部分内容阅读
目的通过甘精胰岛素联用那格列奈与预混人工合成人胰岛素(优泌林30R)治疗高龄2型糖尿病患者的比较,探讨前者的疗效及安全性。方法将50例75岁以上的2型糖尿病患者随机分成甘精胰岛素与那格列奈组(G组)25例和优泌林30R组(N组)25例,根据血糖情况调整用药剂量,治疗12周后比较两组的空腹血糖、餐后2 h血糖、糖化血红蛋白(HbA1C)、低血糖发生率及体质量指数(BMI)。结果G组在餐后2 h血糖和低血糖发生率方面均低于N组,差异有统计学意义(P<0.05);在空腹血糖、HbA1C和BMI方面差异无统计学意义(P>0.05)。结论甘精胰岛素与那格列奈联用对于高龄2型糖尿病患者是一种安全、有效且方便的治疗方案,低血糖的发生率很小,尤其是对那些有较差的认知力、活动不方便、视力差或合并多种慢性病的高龄2型糖尿病患者尤为适用。
Objective To compare the efficacy and safety of insulin glargine combined with nateglinide and pre-mixed synthetic human insulin (30GU) in the treatment of elderly patients with type 2 diabetes mellitus. Methods Fifty patients with type 2 diabetes mellitus over the age of 75 were randomly divided into 25 cases of glargine and nateglinide group (G group) and 25 cases of superior bleeding group 30R group (N group). The dosage was adjusted according to the blood glucose level, After 12 weeks, fasting blood glucose, postprandial blood glucose, HbA1C, incidence of hypoglycemia and body mass index (BMI) were compared between the two groups. Results There was no significant difference in fasting blood glucose, HbA1C and BMI between group G and group N at 2 h postprandial glucose (P <0.05) . Conclusions Glargine and nateglinide are a safe, effective and convenient treatment for elderly patients with type 2 diabetes. The incidence of hypoglycemia is very low, especially for those with poor cognition and activity Inconvenient, poor eyesight or combined with a variety of chronic diseases in elderly patients with type 2 diabetes is particularly applicable.